McGill and MUHC team up with LSU Health New Orleans to advance Usher Syndrome antisense therapy research

Live 2019
Researchers collaborate to treat vision loss linked to Usher thanks to a 1.74 million USD grant from the National Institutes of Health

 

Source: LSU and MUHC

Developing an effective treatment using antisense therapy for vision loss in Usher – a rare genetic disease characterized by concurrent hearing and vision loss – is the long-term goal of a research project led by Jennifer J. Lentz, PhD, Associate Professor at LSU Health New Orleans Neuroscience Center of Excellence and Departments of Otorhinolaryngology, Genetics and Ophthalmology in collaboration with Dr. Robert K. Koenekoop, Professor in the Departments of Pediatric Surgery and Ophthalmology at McGill University’s Faculty of Medicine and  Senior Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC). This project was awarded a $1.74 million USD five-year grant by the National Eye Institute of the National Institutes of Health (NIH.)

Usher syndrome, which affects all aspects of life, including health, education, social activities and employment, is associated with mutations in 16 different genes creating four distinct clinical types. Lentz’s research targets the human 216A mutation in the USH1C gene that causes Type 1C Usher Syndrome in the Acadian population.

“The first aim of this study is to identify and characterize an USH1C-ASO drug therapy molecule that most effectively targets the 216A mutation and treats vision loss,” says Lentz.

The second aim is to determine which visual tests are the most likely to document improvement in vision and safety, i.e., the most robust clinical endpoints and identify potential trial participants to guide a clinical trial. Dr. Koenekoop, who is also Chief of Pediatric Ophthalmology at the Montreal Children’s Hospital of MUHC, will contribute to the research clinical aspect along with Lentz and Dr. Maria Reinoso, Associate Professor of Ophthalmology at LSU Health New Orleans. To date, 62 USH1C patients have been identified in the three participating clinical centers.

“I am extremely excited to continue working with the LSU group headed by Dr. Lentz,” says Dr. Koenekoop. “We, in Montreal, have been following USH1C patients for over 20 years, and this next step in our collaboration and novel study provides solid hope for them”.

The clinical research is additionally supported by a $40,000 donation to Lentz’s and Reinoso’s work from Ush One See Foundation, and a $453,920 grant from Fighting Blindness Canada to Koenekoop’s research.

For more information, read LSU Health New Orleans Press Release

 

October 24 2019

Be Sociable, Share!

Comments are closed.